AIM: To analyze the relationship between the serum lectin-like oxidized low-density lipoprotein receptor-1(LOX-1) levels and clinical and histopathological features of biopsy-confirmed nonalcoholic fatty liver disease...AIM: To analyze the relationship between the serum lectin-like oxidized low-density lipoprotein receptor-1(LOX-1) levels and clinical and histopathological features of biopsy-confirmed nonalcoholic fatty liver disease(NAFLD) patients.METHODS: Fifty-three consecutive,biopsy-proven NAFLD patients(31 males and 22 females,mean age 42.5 ± 9.6 years) and 26 age- and gender-matched,healthy controls(14 males and 12 females,mean age 39 ± 10.7 years) were included.The patientswith NAFLD were consecutive patients who had been admitted to the hepatology outpatient clinic within the last year and had been diagnosed with NAFLD as the result of liver biopsy.The healthy controls were individuals who attended the outpatient clinic for routine health control and had no known chronic illnesses.The histological evaluation was conducted according t o t he N AF LD ac t ivi ty scoring syst em recommended by The National Institute of Diabetes and Digestive and Kidney Diseases Nonalcoholic Steatohepatitis Clinical Research Network.The serum LOX-1 levels were measured using an ELISA kit(Life Science Inc.USCN.Wuhan,Catalog No.E1859Hu) in both patients and healthy controls.A receiver operating characteristic(ROC) curve analysis was used to identify the optimal cutoff value of LOX-1 and thereby distinguish between patients with nonalcoholic steatohepatitis(NASH) and healthy controls.A P-value < 0.05 was considered statistically significant.RESULTS: NAFLD and healthy control groups were similar in terms of age and sex.NAFLD patients consisted of 8 patients with simple steatosis(15%),27 with borderline NASH(51%) and 18 with definitive NASH(34%).Metabolic syndrome was found in 62.2% of the patients with NAFLD.The mean serum LOX-1 level in biopsy-proven NAFLD patients was 8.49 ± 6.43 ng/m L compared to 4.08 ± 4.32 ng/m L in healthy controls(P = 0.001).The LOX-1 levels were significantly different between controls,simple steatosis and NASH(borderline+definite) cases(4.08 ± 4.32 ng/m L,6.1 ± 6.16 ng/m L,8.92 ± 6.45 ng/m L,respectively,P = 0.004).When the cut-off value for the serum LOX-1 level was set at 5.35 ng/m L,and a ROC curve analysis was performed to distinguish between steatohepatitis patients and controls; the sensitivity and specificity of the serum LOX-1 level were 69.8% and 69.2%,respectively.CONCLUSION: The serum LOX-1 levels were significantly higher in NAFLD patients than in healthy controls.Additionally,the serum LOX-1 levels could differentiate between steatohepatitis patients and healthy controls.展开更多
BACKGROUND Several risk scores have been developed to predict hepatocellular carcinoma(HCC)risk in chronic hepatitis B(CHB)patients.The majority of risk scores are based on pretreatment variables that are no longer co...BACKGROUND Several risk scores have been developed to predict hepatocellular carcinoma(HCC)risk in chronic hepatitis B(CHB)patients.The majority of risk scores are based on pretreatment variables that are no longer considered risk factors for HCC development due to the suppression of hepatitis B virus replication early in the course of potent antiviral treatment in most patients.The PAGE-B score,which is based on platelet levels,age and sex,has been shown to accurately predict HCC risk in CHB patients on antiviral treatment in various populations.AIM We aimed to evaluate the PAGE-B score in predicting HCC risk in Turkish CHB patients on antiviral treatment.METHODS In this study,we recruited 742 CHB patients who had been treated with tenofovir disoproxil fumarate or entecavir for≥1 year.Risk groups were determined according to the PAGE-B scores as follows:≤9,low;10-17,moderate and≥18,high.The cumulative HCC incidences in each risk group were computed using Kaplan-Meier analysis and were compared using the log-rank test.The accuracy of the PAGE-B score in predicting HCC risk was evaluated using a timedependent area under the receiver operating characteristic(AUROC)curve at all study time points.Univariate and multivariate logistic regression analyses were used to assess the risk factors for HCC development.RESULTS The mean follow-up time was 54.7±1.2 mo.HCC was diagnosed in 26 patients(3.5%).The cumulative HCC incidences at 1,3,5 and 10 years were 0%,0%,0%and 0.4%in the PAGE-B low-risk group;0%,1.2%,1.5%and 2.1%in the PAGE-B moderate-risk group;and 5%,11.7%,12.5%,and 15%in the PAGE-B high-risk group,respectively(log-rank P<0.001).The AUROCs of the PAGE-B score in the prediction of HCC development at 1,3,5 and 10 years were 0.977,0.903,0.903 and 0.865,respectively.In the multivariable analysis,older age,male sex,lower platelet levels,presence of cirrhosis,and absence of alanine aminotransferase normalization at month 6 were associated with HCC development(all P<0.05).CONCLUSION The PAGE-B score is a practical tool to predict HCC risk in Turkish patients with CHB and may be helpful to improve surveillance strategies.展开更多
文摘AIM: To analyze the relationship between the serum lectin-like oxidized low-density lipoprotein receptor-1(LOX-1) levels and clinical and histopathological features of biopsy-confirmed nonalcoholic fatty liver disease(NAFLD) patients.METHODS: Fifty-three consecutive,biopsy-proven NAFLD patients(31 males and 22 females,mean age 42.5 ± 9.6 years) and 26 age- and gender-matched,healthy controls(14 males and 12 females,mean age 39 ± 10.7 years) were included.The patientswith NAFLD were consecutive patients who had been admitted to the hepatology outpatient clinic within the last year and had been diagnosed with NAFLD as the result of liver biopsy.The healthy controls were individuals who attended the outpatient clinic for routine health control and had no known chronic illnesses.The histological evaluation was conducted according t o t he N AF LD ac t ivi ty scoring syst em recommended by The National Institute of Diabetes and Digestive and Kidney Diseases Nonalcoholic Steatohepatitis Clinical Research Network.The serum LOX-1 levels were measured using an ELISA kit(Life Science Inc.USCN.Wuhan,Catalog No.E1859Hu) in both patients and healthy controls.A receiver operating characteristic(ROC) curve analysis was used to identify the optimal cutoff value of LOX-1 and thereby distinguish between patients with nonalcoholic steatohepatitis(NASH) and healthy controls.A P-value < 0.05 was considered statistically significant.RESULTS: NAFLD and healthy control groups were similar in terms of age and sex.NAFLD patients consisted of 8 patients with simple steatosis(15%),27 with borderline NASH(51%) and 18 with definitive NASH(34%).Metabolic syndrome was found in 62.2% of the patients with NAFLD.The mean serum LOX-1 level in biopsy-proven NAFLD patients was 8.49 ± 6.43 ng/m L compared to 4.08 ± 4.32 ng/m L in healthy controls(P = 0.001).The LOX-1 levels were significantly different between controls,simple steatosis and NASH(borderline+definite) cases(4.08 ± 4.32 ng/m L,6.1 ± 6.16 ng/m L,8.92 ± 6.45 ng/m L,respectively,P = 0.004).When the cut-off value for the serum LOX-1 level was set at 5.35 ng/m L,and a ROC curve analysis was performed to distinguish between steatohepatitis patients and controls; the sensitivity and specificity of the serum LOX-1 level were 69.8% and 69.2%,respectively.CONCLUSION: The serum LOX-1 levels were significantly higher in NAFLD patients than in healthy controls.Additionally,the serum LOX-1 levels could differentiate between steatohepatitis patients and healthy controls.
文摘BACKGROUND Several risk scores have been developed to predict hepatocellular carcinoma(HCC)risk in chronic hepatitis B(CHB)patients.The majority of risk scores are based on pretreatment variables that are no longer considered risk factors for HCC development due to the suppression of hepatitis B virus replication early in the course of potent antiviral treatment in most patients.The PAGE-B score,which is based on platelet levels,age and sex,has been shown to accurately predict HCC risk in CHB patients on antiviral treatment in various populations.AIM We aimed to evaluate the PAGE-B score in predicting HCC risk in Turkish CHB patients on antiviral treatment.METHODS In this study,we recruited 742 CHB patients who had been treated with tenofovir disoproxil fumarate or entecavir for≥1 year.Risk groups were determined according to the PAGE-B scores as follows:≤9,low;10-17,moderate and≥18,high.The cumulative HCC incidences in each risk group were computed using Kaplan-Meier analysis and were compared using the log-rank test.The accuracy of the PAGE-B score in predicting HCC risk was evaluated using a timedependent area under the receiver operating characteristic(AUROC)curve at all study time points.Univariate and multivariate logistic regression analyses were used to assess the risk factors for HCC development.RESULTS The mean follow-up time was 54.7±1.2 mo.HCC was diagnosed in 26 patients(3.5%).The cumulative HCC incidences at 1,3,5 and 10 years were 0%,0%,0%and 0.4%in the PAGE-B low-risk group;0%,1.2%,1.5%and 2.1%in the PAGE-B moderate-risk group;and 5%,11.7%,12.5%,and 15%in the PAGE-B high-risk group,respectively(log-rank P<0.001).The AUROCs of the PAGE-B score in the prediction of HCC development at 1,3,5 and 10 years were 0.977,0.903,0.903 and 0.865,respectively.In the multivariable analysis,older age,male sex,lower platelet levels,presence of cirrhosis,and absence of alanine aminotransferase normalization at month 6 were associated with HCC development(all P<0.05).CONCLUSION The PAGE-B score is a practical tool to predict HCC risk in Turkish patients with CHB and may be helpful to improve surveillance strategies.
